Titre : Antigène HLA-B13

Antigène HLA-B13 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Programmed Cell Death 1 Receptor
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Antigène HLA-B13 : Questions médicales les plus fréquentes", "headline": "Antigène HLA-B13 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Antigène HLA-B13 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-20", "dateModified": "2025-02-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Antigène HLA-B13" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Antigènes HLA-B", "url": "https://questionsmedicales.fr/mesh/D015235", "about": { "@type": "MedicalCondition", "name": "Antigènes HLA-B", "code": { "@type": "MedicalCode", "code": "D015235", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.050.705.552.450.380" } } }, "about": { "@type": "MedicalCondition", "name": "Antigène HLA-B13", "alternateName": "HLA-B13 Antigen", "code": { "@type": "MedicalCode", "code": "D059908", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Apostolos P Georgopoulos", "url": "https://questionsmedicales.fr/author/Apostolos%20P%20Georgopoulos", "affiliation": { "@type": "Organization", "name": "The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA." } }, { "@type": "Person", "name": "Lisa M James", "url": "https://questionsmedicales.fr/author/Lisa%20M%20James", "affiliation": { "@type": "Organization", "name": "The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA." } }, { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Arie Admon", "url": "https://questionsmedicales.fr/author/Arie%20Admon", "affiliation": { "@type": "Organization", "name": "Faculty of Biology, Technion Israel Institute of Technology, Haifa, Israel admon@technion.ac.il Michael.peled@sheba.health.gov.il." } }, { "@type": "Person", "name": "Spyros A Charonis", "url": "https://questionsmedicales.fr/author/Spyros%20A%20Charonis", "affiliation": { "@type": "Organization", "name": "The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies.", "datePublished": "2023-01-24", "url": "https://questionsmedicales.fr/article/36645031", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/exd.14750" } }, { "@type": "ScholarlyArticle", "name": "MicroRNAs Targeting Programmed Cell Death Protein 1 (PD-1) Promote Natural Killer Cell Exhaustion in Rheumatoid Arthritis.", "datePublished": "2022-12-24", "url": "https://questionsmedicales.fr/article/36640056", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.18502/ijaai.v21i6.11524" } }, { "@type": "ScholarlyArticle", "name": "Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy.", "datePublished": "2023-04-21", "url": "https://questionsmedicales.fr/article/37153623", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2023.1138145" } }, { "@type": "ScholarlyArticle", "name": "A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma.", "datePublished": "2022-09-06", "url": "https://questionsmedicales.fr/article/35758515", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2340/actadv.v102.1062" } }, { "@type": "ScholarlyArticle", "name": "Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.", "datePublished": "2022-11-25", "url": "https://questionsmedicales.fr/article/36442821", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.actbio.2022.11.043" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Antigènes", "item": "https://questionsmedicales.fr/mesh/D000941" }, { "@type": "ListItem", "position": 4, "name": "Isoantigènes", "item": "https://questionsmedicales.fr/mesh/D007519" }, { "@type": "ListItem", "position": 5, "name": "Antigènes d'histocompatibilité", "item": "https://questionsmedicales.fr/mesh/D006649" }, { "@type": "ListItem", "position": 6, "name": "Antigènes HLA", "item": "https://questionsmedicales.fr/mesh/D006680" }, { "@type": "ListItem", "position": 7, "name": "Antigènes HLA-B", "item": "https://questionsmedicales.fr/mesh/D015235" }, { "@type": "ListItem", "position": 8, "name": "Antigène HLA-B13", "item": "https://questionsmedicales.fr/mesh/D059908" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Antigène HLA-B13 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Antigène HLA-B13", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Antigène HLA-B13", "description": "Comment diagnostiquer la présence de HLA-B13 ?\nQuels tests sont utilisés pour HLA-B13 ?\nHLA-B13 est-il associé à des maladies spécifiques ?\nPeut-on détecter HLA-B13 chez tous les individus ?\nQuel rôle joue HLA-B13 dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Antigène HLA-B13", "description": "Quels symptômes sont liés à HLA-B13 ?\nHLA-B13 cause-t-il des symptômes directs ?\nY a-t-il des symptômes spécifiques à HLA-B13 ?\nHLA-B13 est-il lié à des symptômes allergiques ?\nLes symptômes varient selon l'ethnicité ?", "url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Antigène HLA-B13", "description": "Peut-on prévenir les maladies liées à HLA-B13 ?\nY a-t-il des mesures préventives spécifiques ?\nLa vaccination aide-t-elle contre HLA-B13 ?\nLes tests génétiques peuvent-ils prévenir des maladies ?\nL'éducation sur HLA-B13 est-elle importante ?", "url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Antigène HLA-B13", "description": "Quels traitements sont disponibles pour les maladies liées à HLA-B13 ?\nHLA-B13 influence-t-il le choix du traitement ?\nY a-t-il des traitements spécifiques pour HLA-B13 ?\nLes traitements sont-ils efficaces pour HLA-B13 ?\nDes thérapies géniques sont-elles envisagées pour HLA-B13 ?", "url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Antigène HLA-B13", "description": "Quelles complications peuvent survenir avec HLA-B13 ?\nHLA-B13 augmente-t-il le risque de cancer ?\nLes complications sont-elles réversibles ?\nHLA-B13 influence-t-il la gravité des maladies ?\nY a-t-il des complications spécifiques à HLA-B13 ?", "url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Antigène HLA-B13", "description": "Quels sont les facteurs de risque pour HLA-B13 ?\nL'ethnicité influence-t-elle HLA-B13 ?\nLes infections augmentent-elles le risque lié à HLA-B13 ?\nLe mode de vie affecte-t-il HLA-B13 ?\nY a-t-il des tests pour évaluer les facteurs de risque ?", "url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer la présence de HLA-B13 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un test sanguin pour déterminer le typage HLA est utilisé pour diagnostiquer HLA-B13." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour HLA-B13 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de typage HLA, comme la PCR et le séquençage, sont couramment utilisés." } }, { "@type": "Question", "name": "HLA-B13 est-il associé à des maladies spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, HLA-B13 est lié à certaines maladies auto-immunes et infections virales." } }, { "@type": "Question", "name": "Peut-on détecter HLA-B13 chez tous les individus ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Non, HLA-B13 est présent chez une partie de la population, selon l'ethnicité." } }, { "@type": "Question", "name": "Quel rôle joue HLA-B13 dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il aide à évaluer la compatibilité pour les greffes et à identifier des risques de maladies." } }, { "@type": "Question", "name": "Quels symptômes sont liés à HLA-B13 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon les maladies associées, comme des douleurs articulaires ou éruptions." } }, { "@type": "Question", "name": "HLA-B13 cause-t-il des symptômes directs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, HLA-B13 lui-même ne cause pas de symptômes, mais il est associé à des maladies." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques à HLA-B13 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes dépendent des conditions associées, pas de HLA-B13 directement." } }, { "@type": "Question", "name": "HLA-B13 est-il lié à des symptômes allergiques ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "HLA-B13 n'est pas directement lié aux allergies, mais à des maladies auto-immunes." } }, { "@type": "Question", "name": "Les symptômes varient selon l'ethnicité ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la prévalence de HLA-B13 et les maladies associées peuvent varier selon l'ethnicité." } }, { "@type": "Question", "name": "Peut-on prévenir les maladies liées à HLA-B13 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un suivi médical régulier peut aider à détecter précocement." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives spécifiques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des mesures préventives incluent un mode de vie sain et la gestion du stress." } }, { "@type": "Question", "name": "La vaccination aide-t-elle contre HLA-B13 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "La vaccination peut aider à prévenir certaines infections, mais pas directement HLA-B13." } }, { "@type": "Question", "name": "Les tests génétiques peuvent-ils prévenir des maladies ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier les risques et permettre une surveillance préventive." } }, { "@type": "Question", "name": "L'éducation sur HLA-B13 est-elle importante ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation sur HLA-B13 et ses implications peut aider à mieux gérer les risques." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les maladies liées à HLA-B13 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des immunosuppresseurs et des thérapies ciblées selon la maladie." } }, { "@type": "Question", "name": "HLA-B13 influence-t-il le choix du traitement ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la présence de HLA-B13 peut influencer le choix des traitements immunologiques." } }, { "@type": "Question", "name": "Y a-t-il des traitements spécifiques pour HLA-B13 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitement spécifique pour HLA-B13, mais pour les maladies associées." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces pour HLA-B13 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité des traitements dépend de la maladie associée et de la réponse individuelle." } }, { "@type": "Question", "name": "Des thérapies géniques sont-elles envisagées pour HLA-B13 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours sur les thérapies géniques, mais elles ne sont pas encore disponibles." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec HLA-B13 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des maladies auto-immunes et des réactions aux greffes." } }, { "@type": "Question", "name": "HLA-B13 augmente-t-il le risque de cancer ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent un lien entre HLA-B13 et un risque accru de certains cancers." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "HLA-B13 influence-t-il la gravité des maladies ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, HLA-B13 peut influencer la gravité et l'évolution de certaines maladies auto-immunes." } }, { "@type": "Question", "name": "Y a-t-il des complications spécifiques à HLA-B13 ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications spécifiques dépendent des maladies associées, pas de HLA-B13 lui-même." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour HLA-B13 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, l'ethnicité et des infections virales." } }, { "@type": "Question", "name": "L'ethnicité influence-t-elle HLA-B13 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la prévalence de HLA-B13 varie selon les groupes ethniques et les populations." } }, { "@type": "Question", "name": "Les infections augmentent-elles le risque lié à HLA-B13 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections peuvent déclencher des maladies auto-immunes chez les porteurs de HLA-B13." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il HLA-B13 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut réduire le risque de maladies associées à HLA-B13." } }, { "@type": "Question", "name": "Y a-t-il des tests pour évaluer les facteurs de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests génétiques et des évaluations médicales peuvent aider à identifier les risques." } } ] } ] }

Sources (10000 au total)

Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.

Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand programmed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, includi...

Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.

Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC) by the European... Post hoc analysis of the Chinese JUPITER-06 study focusing on efficacy stratified by PD-L1 tumor proportion score (TPS; using JS311 antibody) was conducted. Electronic databases were searched to ident... The post hoc analysis of JUPITER-06 showed more prominent clinical benefit with PD-1 antibody plus chemotherapy than with chemotherapy alone in both the high and low PD-L1-expressing subgroups. Five r... This study provided novel evidence supporting the superiority of PD-1 antibody plus chemotherapy to chemotherapy alone in patients with advanced ESCC with low PD-L1 expression. Further studies of pred...

Association between programmed death-1 pathway and major depression.

Major depression (MD) may be associated with inflammation and immunity. PD-1 (programmed death-1), PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2) are among the inhibitory immu... During a period of 2 years, patients with MD and healthy controls were recruited from a medical centre in this study. The diagnosis of MD was established according to the DSM-5 criteria. The severity ... A total of 54 patients with MD and 38 healthy controls were recruited. According to the analyses, there is a significantly higher PD-L2 level in MD than in healthy controls and lower PD-1 level after ... It was found that PD-1 pathway might play an important role in MD. We need a large sample to prove these results in the future....

Programmed cell death protein 1 is a marker for neoadjuvant chemotherapy response in triple-negative breast cancer.

Tumor-infiltrating lymphocytes are detectable in up to 75% of triple-negative breast cancer. The composition of these infiltrates may influence prognosis and is not known regarding regulatory or effec... This was a retrospective observational study. Clinical and pathological data from 38 triple-negative breast cancer patients treated with neoadjuvant chemotherapy at the University Hospital (HUCFF/UFRJ... Statistically significant changes in stromal tumor-infiltrating lymphocyte categories were observed before and post-neoadjuvant chemotherapy, with 32% of intermediate cases becoming high. The correlat... In this study, we observed that chemotherapy significantly increases stromal tumor-infiltrating lymphocytes, CD8 T cells, as well as CD8/FoxP3 ratio. Most importantly, programmed cell death protein 1 ...